je.st
news
Tag: treatment
Costs Associated with Skin Cancer Treatment Surge
2014-11-11 06:07:04| Happi Breaking News
Rises five times as fast as other cancer treatments and underscores the need for prevention efforts, author says.
Tags: costs
treatment
skin
cancer
Interim Data from Proof-of-Concept Study of Mercks Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting
2014-11-10 00:53:00| Merck.com - Research & Development News
Dateline City: BOSTON Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Mercks Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
study
presented
11.07.14 -- New Research In Pharmacologic Decision-Making In Treatment Of Focal Epilepsy
2014-11-06 01:03:17| drugdiscoveryonline News Articles
11/07/14 Drug Discovery Online Newsletter
Tags: of
research
treatment
focal
Optimarin Opens New Ballast Water Treatment Market with EX Approval
2014-11-05 17:36:00| Ship Technology
Ballast water treatment (BWT) specialist Optimarin has announced that it has received full EX approval for a modified version of its market proven Optimarin Ballast System (OBS).
Tags: market
water
treatment
approval
New Research In Pharmacologic Decision-Making In The Treatment Of Focal Epilepsy A Critical Comparison Of Antiepileptic Drugs
2014-11-05 06:37:54| drugdiscoveryonline Home Page
Physicians who treat patients with epilepsy must balance many factors when selecting the appropriate treatment for an individual patient, including seizure type, concomitant antiepileptic drug (AED) therapy, age, comorbid conditions, and even insurance coverage
Tags: of
research
treatment
critical
Sites : [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] next »